| A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors (NCT04685226) | Beijing InnoCare Pharma Tech Co., Ltd. | 2020-09-27 |
| A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 (NCT04689035) | Avilex Pharma | 2020-09-27 |
| The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine (NCT04568811) | Jiangsu Province Centers for Disease Control and Prevention | 2020-09-26 |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (NCT04333706) | University of Southern California | 2020-09-26 |
| Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects (NCT04640012) | Guangzhou JOYO Pharma Co., Ltd | 2020-09-25 |
| A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma (NCT04571138) | Seattle Children's Hospital | 2020-09-25 |
| Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection (NCT04747574) | Tel-Aviv Sourasky Medical Center | 2020-09-25 |
| NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors (NCT04550663) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-09-25 |
| A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects (NCT04703374) | Chong Kun Dang Pharmaceutical | 2020-09-25 |
| A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults (NCT04464460) | Takeda | 2020-09-25 |
| A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC (NCT03963414) | University of Nebraska | 2020-09-25 |
| Bioequivalence Study Between Temozolomide Oral Suspension (Ped-TMZ) and Temodal® Capsules (NCT04467346) | Orphelia Pharma | 2020-09-25 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine (NCT04545749) | United Biomedical Inc., Asia | 2020-09-25 |
| Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia (NCT04485052) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-09-25 |
| Neoadjuvant Atezolizumab in Cutaneous Melanoma (NCT04020809) | The Methodist Hospital Research Institute | 2020-09-25 |
| Study of PF-07265807 in Participants With Metastatic Solid Tumors. (NCT04458259) | Pfizer | 2020-09-24 |
| AAV Gene Therapy Study for Subjects with PKU (NCT04480567) | BioMarin Pharmaceutical | 2020-09-24 |
| A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria (NCT04538794) | Celldex Therapeutics | 2020-09-24 |
| A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics (NCT03754244) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2020-09-24 |
| IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (NCT04335890) | Hasumi International Research Foundation | 2020-09-24 |
| Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254 (NCT04507321) | ViiV Healthcare | 2020-09-24 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors (NCT04452214) | Cantargia AB | 2020-09-24 |
| A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects (NCT04587011) | HK inno.N Corporation | 2020-09-24 |
| Fruquintinib Food Effect and Proton Pump Inhibitor Study (NCT04645940) | Hutchison Medipharma Limited | 2020-09-24 |
| Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (NCT04052555) | National Cancer Institute (NCI) | 2020-09-24 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (NCT04693429) | Laboratorios Sophia S.A de C.V. | 2020-09-24 |
| Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (NCT04659369) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2020-09-24 |
| Phase Ib Clinical Study of Keynatinib (NCT04807881) | Medolution Ltd. | 2020-09-24 |
| Randomised, Placebo-controlled Safety and Pharmacokinetics Study of Novel Rifaximin Formulations in Healthy Volunteers (NCT04529811) | Bausch Health Americas, Inc. | 2020-09-24 |
| Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer (NCT04535323) | Mayo Clinic | 2020-09-23 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692) | IGM Biosciences, Inc. | 2020-09-23 |
| Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers (NCT04580745) | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | 2020-09-23 |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects (NCT04446000) | CSL Behring | 2020-09-23 |
| A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer (NCT04521764) | Mayo Clinic | 2020-09-23 |
| Open Label Study: Treatment of ALS Fatigue With PolyMVA (NCT04557410) | University of Missouri-Columbia | 2020-09-23 |
| Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration (NCT04339764) | National Eye Institute (NEI) | 2020-09-23 |
| A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients (NCT04501276) | Adagene Inc | 2020-09-23 |
| A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer (NCT04298918) | Hoffmann-La Roche | 2020-09-23 |
| A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants (NCT06180954) | Eli Lilly and Company | 2020-09-23 |
| Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants (NCT04564053) | Novartis Pharmaceuticals | 2020-09-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants (NCT04551079) | Takeda | 2020-09-23 |
| A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator (NCT04525599) | Affinivax, Inc. | 2020-09-22 |
| A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors (NCT05187858) | Lupin Ltd. | 2020-09-22 |
| Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects (NCT04540965) | Calithera Biosciences, Inc | 2020-09-22 |
| Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (NCT04475523) | Curis, Inc. | 2020-09-22 |
| Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor (NCT04673396) | Beijing Nuokangda Pharmaceutical Technology Co., Ltd. | 2020-09-22 |
| Tacrolimus as Treatment of Breast Cancer-Related Lymphedema (NCT04541290) | Odense University Hospital | 2020-09-22 |
| A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment (NCT04473664) | Daiichi Sankyo | 2020-09-22 |
| A Study of TEPEZZA Subcutaneous Administration in Healthy Adults (NCT06563856) | Amgen | 2020-09-22 |
| A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread (NCT04132817) | Bristol-Myers Squibb | 2020-09-22 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers (NCT04564456) | Respirent Pharmaceuticals Co Ltd. | 2020-09-22 |
| Efficacy of Adding Dexmedetomidine as an Adjuvant to Bupivacaine in TAP Block and Caudal Block (NCT04926454) | Ain Shams University | 2020-09-22 |
| A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). (NCT04422210) | Hoffmann-La Roche | 2020-09-22 |
| Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer (NCT04304781) | Danielle Kim Turgeon | 2020-09-22 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL (NCT04555811) | Masonic Cancer Center, University of Minnesota | 2020-09-22 |
| Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19 (NCT04632706) | MedinCell S.A | 2020-09-22 |
| DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer (NCT04509596) | Dizal Pharmaceuticals | 2020-09-21 |
| A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants (NCT04565678) | Agios Pharmaceuticals, Inc. | 2020-09-21 |
| Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain (NCT04530071) | CHABiotech CO., Ltd | 2020-09-21 |
| PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT04556617) | Opna Bio LLC | 2020-09-21 |
| Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition (NCT05197517) | Rania Mahmoud Mohamed | 2020-09-21 |
| A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS (NCT04582201) | MiNK Therapeutics | 2020-09-21 |
| Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects (NCT04563702) | Vaxart | 2020-09-21 |
| Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer (NCT04557306) | CHABiotech CO., Ltd | 2020-09-21 |
| Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) (NCT04210375) | Salubris Biotherapeutics Inc | 2020-09-21 |
| Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation (NCT04564313) | Third Affiliated Hospital, Sun Yat-Sen University | 2020-09-21 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (NCT04623944) | Nkarta, Inc. | 2020-09-21 |
| Oral Nafamostat in Healthy Volunteers (NAF-101) (NCT04406415) | Ensysce Biosciences | 2020-09-21 |
| A Study of Qishenyiqi Dripping Pills in Healthy Participants (NCT04471298) | Tasly Pharmaceutical Group Co., Ltd | 2020-09-21 |
| A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors (NCT04467853) | Shanghai East Hospital | 2020-09-21 |
| Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19 (NCT04497948) | Acerta Pharma BV | 2020-09-21 |
| Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. (NCT04358237) | Antonio Calles Blanco | 2020-09-21 |
| The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) (NCT05361031) | Helixmith Co., Ltd. | 2020-09-21 |
| Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH (NCT04555434) | Chuncheon Sacred Heart Hospital | 2020-09-20 |
| Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (NCT04555577) | M.D. Anderson Cancer Center | 2020-09-20 |
| ICG-PDT, Periimplantitis, Diabetes Mellitus (NCT04833569) | King Saud University | 2020-09-20 |
| Atlas of Intracranial Recordings on Cortical Responses After Functional tACS (NCT04560959) | Xuanwu Hospital, Beijing | 2020-09-20 |
| Ivermectin Reproposing for Mild Stage COVID-19 Outpatients (NCT04784481) | Ministry of Public Health, Argentina | 2020-09-20 |
| Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine (NCT04530357) | Research Institute for Biological Safety Problems | 2020-09-19 |
| A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects (NCT06094738) | Corcept Therapeutics | 2020-09-19 |
| Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma (NCT04116359) | National Cancer Institute (NCI) | 2020-09-18 |
| Raltitrexed in HIPEC (NCT04761185) | Fudan University | 2020-09-18 |
| Effects of Dietary Conditions on Drug Response (NCT04315961) | Johns Hopkins University | 2020-09-18 |
| Dopaminergic restauratIon by intraVEntriculaire Administration (NCT04332276) | University Hospital, Lille | 2020-09-18 |
| Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19) (NCT04567810) | Stanford University | 2020-09-18 |
| A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions (NCT04553978) | Hong Kong WD Pharmaceutical Co., Limited | 2020-09-18 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas (NCT03925428) | National Cancer Institute (NCI) | 2020-09-18 |
| Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations (NCT04688008) | Jiangsu HengRui Medicine Co., Ltd. | 2020-09-18 |
| A Phase 1b Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SR419 (NCT04494815) | Shanghai SIMR Biotechnology Co., Ltd. | 2020-09-18 |
| Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors (NCT05155722) | Bio-Thera Solutions | 2020-09-17 |
| Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (NCT04165967) | University Hospital, Basel, Switzerland | 2020-09-17 |
| A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833 (NCT04546347) | AstraZeneca | 2020-09-17 |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT04370587) | ImmVira Pharma Co. Ltd | 2020-09-17 |
| Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin (NCT04502888) | Shattuck Labs, Inc. | 2020-09-17 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants (NCT04550195) | Bristol-Myers Squibb | 2020-09-17 |
| A Study to Determine the Bioequivalence of Two Doses of Tafamidis (NCT04575116) | Pfizer | 2020-09-17 |
| Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (NCT04491877) | Sanofi Pasteur, a Sanofi Company | 2020-09-17 |
| Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France) (NCT04854538) | Genuine Research Center, Egypt | 2020-09-17 |
| FX-322 in Adults With Age-Related Sensorineural Hearing Loss (NCT04601909) | Frequency Therapeutics | 2020-09-17 |